Emerging therapies for acute coronary syndromes

被引：1
|
作者：
Lilly, Scott M. [1 ,2 ]
Wilensky, Robert L. [1 ,2 ]
机构：
[1] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA
[2] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA
来源：
FRONTIERS IN PHARMACOLOGY | 2011年 / 2卷
关键词：
prasugrel; ticagrelor; bivalirudin; fondaparinux; dabigatran; vorapaxar; ELEVATION MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; FACTOR-XA INHIBITOR; OPTIMIZING PLATELET INHIBITION; AMI HARMONIZING OUTCOMES; EARLY INVASIVE STRATEGY; HIGH-RISK PATIENTS; UNFRACTIONATED HEPARIN; DOUBLE-BLIND; ACUTE CATHETERIZATION;
D O I：
10.3389/fphar.2011.00061
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In the majority of cases acute coronary syndromes (ACS) are caused by activation and aggregation of platelets and subsequent thrombus formation leading to a decrease in coronary artery blood flow. Recent focus on the treatment of ACS has centered on reducing the response of platelets to vascular injury as well as inhibiting fibrin deposition. Novel therapies include more effective P2Y12 receptor blockers thereby reducing inter-individual variability, targeting the platelet thrombin receptor (protease activated receptor 1) as well as directly inhibiting factor Xa or thrombin activity. In this review we discuss the clinical data evaluating the effectiveness of these various new ACS treatment options.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Novel risk factors for acute coronary syndromes and emerging therapies
    Tong, David C.
    Wilson, Andrew M.
    Layland, Jamie
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 220 : 815 - 824
  • [2] Current and emerging anti-thrombotic therapies for acute coronary syndromes
    Topol, EJ
    [J]. JOURNAL OF INVASIVE CARDIOLOGY, 1998, 10 : 2D - 7D
  • [3] Easing the economic burden of acute coronary syndromes: Cost-effectiveness of emerging therapies
    Nutescu, Edith A.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (16): : S444 - S450
  • [4] Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes
    Hanna, Elias B.
    Glancy, David Luke
    Saucedo, Jorge F.
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (01) : 61 - 70
  • [5] Adjunctive therapies in the treatment of acute coronary syndromes
    Miller, WL
    Reeder, GS
    [J]. MAYO CLINIC PROCEEDINGS, 2001, 76 (04) : 391 - 405
  • [6] Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes
    Elias B. Hanna
    David Luke Glancy
    Jorge F. Saucedo
    [J]. Cardiovascular Drugs and Therapy, 2010, 24 : 61 - 70
  • [7] New antiplatelet therapies for acute coronary syndromes
    Rich J.D.
    Wiviott S.D.
    [J]. Current Cardiology Reports, 2007, 9 (4) : 303 - 311
  • [8] Antiplatelet and antithrombin therapies in the acute coronary syndromes
    Alexander, JH
    Harrington, RA
    [J]. CURRENT OPINION IN CARDIOLOGY, 1997, 12 (04) : 427 - 437
  • [9] Evaluating the risks of therapies for acute coronary syndromes - Reply
    Fitchett, D
    Goodman, S
    Langer, A
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2001, 165 (10) : 1302 - 1303
  • [10] Emerging pathophysiological relevance for neutrophils in acute coronary syndromes
    Montecucco, Fabrizio
    Carbone, Federico
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 (01) : 111 - 112
12345